Technology produces novel heavy chain-only antibodies for bi-specific, single domain antibodies or CAR-Ts
CAMBRIDGE, Mass. & ROTTERDAM, The Netherlands, & SHANGHAI--(BUSINESS WIRE)--Harbour BioMed today announced a worldwide multi-year license agreement with a Top-Ten, global pharmaceutical leader in immunology and immuno-oncology to discover, develop, and commercialize biologic therapeutics using Harbour’s patented HCAb transgenic mouse platform. The HCAb platform generates novel, fully human heavy chain only antibodies to accelerate the discovery and development of advanced biologic therapeutics, especially single domain antibodies, bi-specific and multi-specific antibodies, and CAR-Ts.
“Drug discovery in the burgeoning fields of immuno-oncology and immunotherapy is relying increasingly on advanced biological approaches to selectively attack one or more immune targets and modulate the immune system to treat cancer and other diseases,” said Dr. Jingsong Wang, CEO of Harbour BioMed. “The HCAb platform is emerging as a powerful technology to enable next generation biologic discovery for our internal portfolio and a select group of licensing partners. This new license agreement, with one of the world’s leading pharmaceutical companies, is a significant endorsement of our approach.”
Under the terms of the agreement, Harbour BioMed will receive an upfront payment and will be further eligible to receive a combination of development and sales related milestone payments and royalties. Specific financial details were not disclosed. Harbour BioMed signed the non-exclusive license through its wholly-owned subsidiary, Harbour Antibodies HCAb BV.
About Harbour Mice™ Technology
Harbour Mice™ technology consists of two fully human transgenic mouse platforms that can produce both full-length human IgG molecules (H2L2) and heavy chain only human IgG molecules (HCAb). The Harbour Mice™ technology is owned by Harbour Antibodies H2L2 BV and Harbour Antibodies HCAb BV, which are subsidiaries of Harbour BioMed.